Linus Health Presents New Data on AI-Based Cognitive Assessments at AAIC 2023

Researchers share findings from eight new studies on ability of digital solutions to accelerate early detection of Alzheimer’s and other dementias

Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility

BioIVT Acquires PrecisionMed, a Leading Global Provider of Biospecimens for Neurology and Oncology Research

PrecisionMed developed and manages the largest, private, global repository of longitudinally collected human cerebrospinal fluid (CSF) samples for scientific research.

AARDEX Group Announced as Founder Member of CancerX Initiative to Drive Innovation in the Fight Against Cancer

AARDEX Group Announced as Founder Member of CancerX Initiative to Drive Innovation in the Fight Against Cancer Adherence specialists join multi-stakeholder initiative to improve long-term pathways for cancer patients and meet the challenge of oral treatments.

Adlib + Generis Partnership: A “Game Changer” for Regulated Companies

Generis and Adlib Software have announced the launch of a software connector that provides seamless integration between their industry-leading technology platforms.

PromoCell Launches PromoExQ MSC Growth Medium XF for GMP Compliant Isolation and Expansion of Mesenchymal Stem Cells

PromoCell has announced the launch of PromoExQ MSC Growth Medium XF, a serum- and xeno-free cell culture medium designed for GMP-compliant isolation and expansion of mesenchymal stem cells for cell therapy manufacturing applications.

Vector Laboratories Acquires Quanta BioDesign to Continue Growth Strategy of Strengthening Development and Manufacturing Services for Life Science and Biopharma Customers

Acquisition expands customers' ability to accelerate their advanced bioconjugate and payload delivery design innovation

Cytel acquires French group stève consultants to further expand value evidence and real-world analytics capabilities

Cytel Inc. has acquired stève consultants, specialists in market access, real-world (RWE), and health economics and outcomes research (HEOR).

Endor Labs Recognized as a Cool Vendor in the 2023 Gartner® Cool Vendors™ in Platform Engineering for Scaling Application Security Practices

Startup, Endor Labs has been named a Gartner Cool Vendor in Platform Engineering for Scaling Application Security Practices, highlighting the company’s commitment to providing cutting-edge solutions that address the challenges faced by platform engineering and DevSecOps teams in meeting application security needs.

Inizio Engage launches Patient Access Services – an integrated suite of patient support services to enhance access and adherence for specialty therapies

DoseMe Expands Leadership Team with Appointments of Paul Edwards to CEO, John Hardesky to CCO and Sharmeen Roy to Chief Strategy & Science Officer

DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring and creators of DoseMeRx and DoseMe Analytics, today announced the appointments of Paul Edwards to Chief Executive Officer, John Hardesky to the role of Chief Commercial Officer and Dr. Sharmeen Roy, PharmD, BCPS, to Chief Strategy and Science Officer.

GigaIO Introduces the First Ever 32 GPU Single-Node Supercomputer for Generative AI and Accelerated Computing

Genedata Announces Partnership with Dragonfly Therapeutics to Support Novel Immune Engager R&D

Genedata Biologics supports R&D processes at innovative biopharmaceutical company developing breakthrough immunotherapies for the treatment of cancer and chronic inflammatory diseases

Phastar's B Corp™ certification affirms its status as a 'force for good' organization

Phastar's B Corp™ certification affirms its status as a 'force for good' organization International certification recognizes leading global specialist biometrics CRO’s commitment and leadership in corporate social responsibility and sustainable business practices.

Skyelarke furthers its mission to break down barriers to clinical trial participation, with new SkyePay enhancements

Skyelarke furthers its mission to break down barriers to clinical trial participation, with new SkyePay enhancements Cary, North Carolina- July 11th, 2023: Skyelarke, a health tech company, has announced some significant new additions to SkyePay, a cutting-edge patient payment technology built by and for the clinical research industry.

NCC Group Welcomes New Chief Technology Officer, Siân John

NCC Group, one of the world’s largest security consultancies with over 35 global offices, 2,000 employees in 12 countries and 14,000 clients, today appointed Siân John as Chief Technology Officer. Joining from Microsoft and with 25 years of cybersecurity experience across strategy, business risk, privacy, and technology, Siân will drive innovation, insights and intelligence at the firm through close interaction with clients, industry, and academia.

Cotiviti Introduces Prepay Claim Review Solution for Coordination of Benefits (COB) Validation

New addition to comprehensive COB suite enables health plans to improve claim accuracy while reducing provider and member abrasion

JPA Health Unveils GRETEL Trails: Revolutionizing Integrated Healthcare Marketing with AI-Powered Insight Engine and Chatbot

Pharma Targeting Launch ‘Partner Identifier’ to Intelligently Connect the Dots between Data and Business Opportunity for Pharma Clients

Pharma Targeting, part of the The Targeting Group and a leading global pharmaceutical market intelligence and data company, has unveiled its latest pioneering initiative, designed to help pharma and biotech companies find the partners they need to get funded, noticed, and faster to market. The service uses data-driven intelligence to help customers identify and engage with the right partner, whether it be for licencing, in-licensing, funding, distribution, or any other business need.

LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT BRITAIN FOR MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.1

Mirikizumab is the first IL-23p19 targeted biologic to demonstrate efficacy for induction and maintenance therapy of moderately to severely active Ulcerative Colitis. Marketing authorisation was based on two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2. In both studies mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission1 Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-11